<DOC>
	<DOCNO>NCT00933036</DOCNO>
	<brief_summary>The clinical trial conduct evaluate performance Crosstrees System reduce pain decrease risk cement leakage associate vertebroplasty kyphoplasty .</brief_summary>
	<brief_title>Clinical Evaluation Crosstrees Pod™ Treatment Pathologic Fracture Vertebral Body ( Levels T4 - L5 ) Adult Patients</brief_title>
	<detailed_description>Every year United States 700,000 people suffer compression fracture spinal column , number people affect much high across world . Osteoporosis main cause fracture vertebral body . Other cause vertebral fracture include malignant process include benign lesion ( hemangioma ) malignant lesion ( metastatic cancer , myeloma ) , infection trauma ; however , osteoporosis far main cause problem . In normal person , vertebral body compose porous structure call trabecular spongy bone encapsulate within thin external cap cortical ( dense ) bone . In person osteoporosis , trabeculae form central porous bone become thinner weaker . When occurs , vertebral body begin fracture become deform . This deformation vertebral body classify three type , accord shape : wedge , biconcave , crush . The degree severity deformation classify grade A1.1 , grade A1.2 , grade A1.3 The Crosstrees PVA™ Pod™ device design percutaneously provide controlled delivery PMMA bone filler material vertebral augmentation . The Crosstrees PVA System Percutaneous Vertebral Augmentation ( PVA ) design use Crosstrees Fortibrae PMMA . The system novel provide ability control delivery PMMA vertebral body without need additional permanent implant remain within patient . The Crosstrees System Percutaneous Vertebral Augmentation use Crosstrees Access Tools , regulate Class I exempt orthopedic manual surgical instrument .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Fractures , Spontaneous</mesh_term>
	<criteria>1 . Patient least 50 year old . 2 . Patient must fracture due diagnose presumed underlying primary secondary osteoporosis ( Patients AO type A1 fracture ( ) may include study ) . 3 . Patient must confirm acute pain tenderness spine near level xray compression deformity OR positive MRI evaluation . 4 . Patient must NOT ( 3 ) three vertebral compression fracture locate T4 L5 . 5 . Subjects affect vertebral body must loss 0 50 % vertebral height compare height adjacent normal vertebral body confirm radiological evaluation . 6 . Subject fracture confirm MRI image include T1 , T2 STIRweighted study determine type presence fracture ( ) . 7 . Subjects affect vertebral body height geometry adequate insertion access instrument 5.2mm OD , determine investigator . 8 . Subjects pain score equal great 5 accord visual analog scale ( VAS ) . 9 . Patient evaluate hematologic disorder condition affect blood coagulation . 10 . Subjects suitable candidate standard vertebroplasty kyphoplasty procedure . 11 . Subject psychosocially , mentally , physically able fully comply protocol include adhere schedule visit , treatment plan , complete form , study procedure . 12 . Subject sign Informed Consent Form prior study related procedure indicate he/she inform pertinent aspect trial . 13 . Failure conservative treatment prior inclusion : a. fail conservative treatment arm ; b. acute therapy treatment arm . 1 . Patient significant vertebral collapse , define &gt; 50 % original height vertebral body , measure near normal vertebral body . Degree collapse determine use height near normal vertebral body represent 100 % divide height collapse vertebral body height normal vertebral body . 2 . Patient compromise spinal canal . 3 . Patient symptomatic spinal stenosis . 4 . Patient painful VCF fracture age great 6 month . 5 . Patients primary tumor bone ( e.g. , osteosarcoma ) solitary plasmacytoma site index VCF . Patients tumor anatomic site index VCF eligible . 6 . Patient fracture extend posterior vertebral body wall . 7 . Patient neurological compromise ( include myelopathy ) instability 8 . Patient retropulsion severe enough cause myelopathy , unless prior surgical decompression perform . 9 . Patient significant clinical comorbidity may potentially interfere longterm data collection followup ( e.g. , dementia , severe comorbid illness ) 10 . Patient require use highdose steroid , IV pain medication , nerve block control chronic back pain unrelated index VCF ( ) . Patients receive highdose steroid treatment cancer ( least 30 day ) eligible . 11 . Patient may require allogenic bone marrow transplantation course study . 12 . Patient need open decompression . 13 . Patient burst fracture , and/or pedicle fracture treatment level . 14 . Patient know suspect allergy PMMA allergy device material use treatment vertebral fracture . Note subject allergy iodinebased contrast , noniodine contrast solution may use . 15 . Patient local pain tenderness correlate MRI evaluation . 16 . Patient coagulation disorder correct : a. patient hematologic disorder condition affect blood coagulation , platelet count internationalize normal ratio ( INR ) , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) value available time interval typical treatment center . The Investigator evaluate range relative normal value treatment center laboratory . 17 . Patient active local systemic infection . 18 . Patient previous current treatment cancer affect level . 19 . Patient previous spine surgery previous injection cement vertebral level surgical procedure . 20 . Patient diabetes mellitus . 21 . Patient MRI contraindication ( e.g. , cerebral aneurysm clip , pacemaker , implanted biostimulators , cochlear implant , penile prosthesis ) 22 . Patient unstable spine indicate neurologic deficit , kyphosis great 30° , compression great 60 % , translation great 4 mm , interspinousprocess widening . 23 . Preexisting condition contrary either PVA vertebroplasty , : a. Irreversible coagulopathy bleed disorder . Note regard reversible coagulopathies : Subjects coumadin anticoagulant may participate . Investigators follow routine practice perioperative discontinuation reinitiation anticoagulant ; b . Any evidence VB systemic infection . 24 . Patient mental deficiency ( e.g. , psychiatric disorder , Alzheimer 's disease , presence alcohol drug abuse ) . 25 . Patient pregnant interested become pregnant study duration . 26 . Patient prisoner ward state . 27 . Patient expect relocate 50 mile study center prior completion study followup period . 28 . Patient AO classification A2 , A3 , B C type fracture 29 . Patient hemangioma , malignant fracture , and/or multiple myeloma site index VCF .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>VCF</keyword>
	<keyword>PVA</keyword>
	<keyword>Vertebroplasty</keyword>
	<keyword>Kyphoplasty</keyword>
	<keyword>Vertebral fracture</keyword>
	<keyword>Pathologic fracture</keyword>
	<keyword>Vertebral augmentation</keyword>
</DOC>